Northview Acquisition CORP 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Profusa, Inc. has entered into a material definitive agreement by issuing a Senior Secured Convertible Promissory Note to Ascent Partners Fund LLC.
Profusa, Inc. has dismissed CBIZ CPAs P.C. as its independent auditor and engaged WithumSmith+Brown, PC, following disclosures of material weaknesses and substantial doubt about its ability to continue as a going concern.
Profusa, Inc. has amended its Senior Secured Convertible Promissory Notes with Ascent Partners Fund LLC, altering conversion prices and waiving certain anti-dilution provisions.
Profusa, Inc. has entered into a material definitive agreement for a Senior Secured Convertible Promissory Note with Ascent Partners Fund LLC, totaling $384,615.38.
Profusa, Inc. has entered into a material definitive agreement by issuing a Senior Secured Convertible Promissory Note for $329,670.33 to Ascent Partners Fund LLC.
Profusa, Inc. announced it has received confirmation from Nasdaq that it complies with the publicly held shares requirement following its recent reverse stock split, ensuring continued trading on the Nasdaq Capital Market.
Profusa, Inc. announced an amendment to its securities purchase agreement, the issuance of a new convertible note, and an exchange of existing notes for preferred stock.
Profusa, Inc. reported Q2 2026 financial results, highlighting progress on its option agreement to acquire G3 Vision Labs, including debt conversions and a reverse stock split, while facing substantial net losses.
Profusa, Inc. has entered into an Option Agreement to acquire G3 Vision Labs, Inc. and its subsidiaries, a move that could significantly expand Profusa's presence in the diagnostics sector.
Profusa, Inc. has appointed Jack Stover as Executive Chairman and CEO, Ben Hwang as President, and Liviu Goldenberg as a director, alongside signing a non-binding term sheet to acquire a commercial-stage health diagnostics and toxicology testing company.
Profusa, Inc. has filed a Form 8-K announcing a 1-for-25 reverse stock split of its common stock, effective July 7, 2026, to reduce outstanding shares and adjust equity awards.
Profusa, Inc. has submitted an Advance Notice to Ascent Partners Fund LLC to purchase shares under their existing equity line of credit arrangement.
Profusa Inc. has amended its Asset Purchase Agreement with Bio Insights LLC, removing provisions for management stock issuance.
Profusa, Inc. has issued an Advance Notice to Ascent Partners Fund LLC to purchase common stock under an existing equity line of credit.
Profusa, Inc. announced its successful transfer to The Nasdaq Capital Market, effective May 15, 2026, meeting interim milestones set by the Nasdaq Hearings Panel.
Profusa, Inc. has received a favorable decision from the Nasdaq Hearings Panel, granting an exception to continue its listing on the Nasdaq Capital Market, subject to meeting specific milestones by July 6, 2026.
Profusa, Inc. has entered into a Note Modification and Conversion Agreement with NorthView Sponsor I LLC, altering terms of an existing promissory note and establishing conditions for its conversion into company stock.
Profusa Inc. has entered into an agreement to acquire the PanOmics Assay platform from Bio Insights LLC for $30 million in convertible preferred stock.
Profusa, Inc. issued a $1.11 million senior secured convertible note and 3.33 million warrants to Ascent Partners Fund LLC.
Profusa, Inc. has entered into a $30 million asset acquisition agreement for a PanOmics platform and issued a new $555,555.55 senior secured convertible note.
Profusa, Inc. announced an amendment to its promissory note with NorthView Sponsor I LLC, extending the maturity date to December 31, 2026.
Profusa, Inc. has entered into an exclusive know-how license agreement with Mayo Foundation for Medical Education and Research for continuous oxygen measurement tools and Critical Limb-Threatening Ischemia applications.
Profusa, Inc. announced a 1-for-75 reverse stock split of its common stock, effective February 9, 2026, to reduce outstanding shares and adjust per-share metrics.
Profusa, Inc. stockholders approved an amendment to its charter allowing for a reverse stock split and ratified the appointment of its independent auditor.
Profusa, Inc. announced Amendment No. 3 to its Securities Purchase Agreement, securing up to $5 million in new funding and revising conversion terms and the Floor Price for its convertible notes.
Profusa, Inc. has amended its securities purchase agreement and convertible promissory note with Ascent Partners Fund LLC, adjusting share sale floor prices and debt repayment terms to facilitate ongoing financing.
Profusa, Inc. announced a significant reduction in net debt to $14 million and achieved key operational milestones, positioning for potential revenue in early 2026.
Profusa, Inc. received a Nasdaq notification for failing to meet the minimum Market Value of Publicly Held Shares requirement, initiating a 180-day compliance period.
Profusa, Inc. outlines its strategic path to achieve $200-$250 million in revenue by 2030, driven by the commercialization of its Lumee tissue oxygen and glucose monitoring platforms in Europe and the U.S.
Profusa, Inc. stockholders approved a significant increase in authorized common stock and the potential issuance of shares related to senior secured convertible notes, enhancing future capital flexibility.